Back to Search Start Over

Cannabidiol Administration Prevents Hypoxia-Ischemia-Induced Hypomyelination in Newborn Rats

Authors :
María Ceprián
Carlos Vargas
Laura García-Toscano
Federica Penna
Laura Jiménez-Sánchez
Svein Achicallende
Izaskun Elezgarai
Pedro Grandes
William Hind
M. Ruth Pazos
José Martínez-Orgado
Source :
Frontiers in Pharmacology, Addi. Archivo Digital para la Docencia y la Investigación, instname, Frontiers in Pharmacology, Vol 10 (2019)
Publication Year :
2019

Abstract

Neonatal hypoxia-ischemia (HI) is a risk factor for myelination disturbances, a key factor for cerebral palsy. Cannabidiol (CBD) protects neurons and glial cells after HI insult in newborn animals. We hereby aimed to study CBD's effects on long-lasting HI-induced myelination deficits in newborn rats. Thus, P7 Wistar rats received s.c. vehicle (HV) or cannabidiol (HC) after HI brain damage (left carotid artery electrocoagulation plus 10% O-2 for 112 min). Controls were non-HI pups. At P37, neurobehavioral tests were performed and immunohistochemistry [quantifying mature oligodendrocyte (mOL) populations and myelin basic protein (MBP) density] and electron microscopy (determining axon number, size, and myelin thickness) studies were conducted in cortex (CX) and white matter (WM). Expression of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF) were analyzed by western blot at P14. HI reduced mOL or MBP in CX but not in WM. In both CX and WM, axon density and myelin thickness were reduced. MBP impairment correlated with functional deficits. CBD administration resulted in normal function associated with normal mOL and MBP, as well as normal axon density and myelin thickness in all areas. CBD's effects were not associated with increased BDNF or GDNF expression. In conclusion, HI injury in newborn rats resulted in long-lasting myelination disturbance, associated with functional impairment. CBD treatment preserved function and myelination, likely as a part of a general neuroprotective effect. This work was supported by grants from the Carlos III Research Institute (ISCiii) according to the Spanish Plan for R+D+I 2008-2011 and the State Plan for Scientific and Technical Research and Innovation 2017-2019, with co-funding from the European Regional Development Funds (FEDER) (FIS-PS1600689), from the Biomedicine Program, Community of Madrid (S2010/BMD-2308) and from GW Research Ltd (GWCRI09119).

Details

ISSN :
16639812
Volume :
10
Database :
OpenAIRE
Journal :
Frontiers in pharmacology
Accession number :
edsair.doi.dedup.....e0e724430369bc317fcc3793946ac901